NewYork-Presbyterian Hospital

AOFAS Honors Two Female Orthopaedic Leaders

Retrieved on: 
Tuesday, February 27, 2024

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”

Key Points: 
  • “I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”
    Over the past 15 years, Dr. Chou has conducted several research studies to examine breast cancer prevalence among female orthopaedic surgeons.
  • Dr. Chou’s research results confirmed higher breast cancer prevalence among female orthopaedic surgeons than the general population, and in a later study, she discovered higher prevalence among female orthopaedic surgeons compared to women in other surgical specialties.
  • Currently, she is leading a study to evaluate cancer risk associated with radiation exposure in male and female orthopaedic surgeons.
  • I applaud AOFAS for taking that initiative with these awards.”
    Funding for the AOFAS Women’s Leadership Initiative is provided by the Orthopaedic Foot & Ankle Foundation, supported by a grant from Treace Medical Concepts, Inc.

Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 23, 2024

In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC).

Key Points: 
  • In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC).
  • Within the non-randomized cohorts of varying conditioning regimens and disease types, Orca-T demonstrated favorable results across clinical outcomes including relapse-free survival (RFS), non-relapse mortality (NRM) and overall survival (OS).
  • The analysis included patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who had a median follow-up time of 15 months and 12 months in the Orca-T and PTCy cohorts, respectively.
  • The outcomes at 12 months are summarized in the table below:

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Retrieved on: 
Thursday, February 15, 2024

HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.

Key Points: 
  • HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.
  • Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.
  • "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.
  • Michelle obtained her medical degree from University of the Witwatersrand, South Africa and is a board-certified pediatric hematologist and oncologist.

Intellihealth's Chief Medical Officer, Dr. Leon Igel, Honored as American Diabetes Association Greater New York's Research Dinner Medical Honoree of the Year

Retrieved on: 
Tuesday, February 13, 2024

NEW YORK, Feb. 13, 2024 /PRNewswire/ -- Intellihealth, a leading clinical services and healthcare technology company that delivers a comprehensive and evidence-based medical model to treat obesity, is proud to announce that Chief Medical Officer, Dr. Leon Igel, has been named 2024's American Diabetes Association® (ADA), Greater New York's Research Dinner Medical Honoree of the Year. The event is taking place on Thursday, May 16 at the Apella at the Alexandria Center for Life Science, NYC. The recognition highlights Dr. Igel's contributions to the field of endocrinology and his groundbreaking work in diabetes and obesity management.

Key Points: 
  • The recognition highlights Dr. Igel's contributions to the field of endocrinology and his groundbreaking work in diabetes and obesity management.
  • His commitment to advancing diabetes care is evident in his innovative approach, particularly in addressing the often-overlooked connection between diabetes and obesity.
  • "It is a privilege to recognize Dr. Leon Igel as the Medical Honoree of the Year," said ADA's Research Dinner Executive Committee Chair Gil Bashe, Finn Partners.
  • Dr. Igel's work with Intellihealth underscores the company's dedication to advancing healthcare through research, technology, and patient-centered approaches.

Accelus Introduces LineSider Modular-Cortical System for Posterior Fixation

Retrieved on: 
Monday, January 29, 2024

This expansion to Accelus’s LineSider Spinal System product portfolio is designed to meet the needs of surgeons who use a modular pedicle screw system from either a standard open approach or a medial-to-lateral cortical approach.

Key Points: 
  • This expansion to Accelus’s LineSider Spinal System product portfolio is designed to meet the needs of surgeons who use a modular pedicle screw system from either a standard open approach or a medial-to-lateral cortical approach.
  • “I highly recommend utilizing the LineSider Modular-Cortical System to complement the FlareHawk expandable interbody fusion device,” said Dr. Ryan Martyn, orthopedic spine surgeon at Spine Colorado.
  • The LineSider Modular-Cortical System builds on Accelus's legacy of developing adaptable, surgeon-centric solutions.
  • "The LineSider Modular-Cortical System exemplifies our commitment to elevating the surgical experience and improving patient outcomes,” said Accelus President and Chief Executive Officer Kevin McGann.

NYC Cosmetic and Facial Plastic Surgeon, Dr. Maurice Khosh, Recognized as a 2024 Top Doctor by Castle Connolly

Retrieved on: 
Thursday, January 25, 2024

NEW YORK, Jan. 25, 2024 /PRNewswire-PRWeb/ -- This prestigious recognition as a 2024 Top Doctor places Dr. Maurice Khosh among the top 7% of all doctors nationwide, a remarkable achievement that highlights his exceptional commitment to patient care and unwavering dedication to delivering high-quality treatment. Dr. Khosh's nomination by his peers adds an extra layer of significance to this recognition. It is a testament to the respect and admiration he has earned from his colleagues, further solidifying his reputation as a true leader in his field. Castle Connolly, with a legacy spanning over 30 years, has consistently identified and honored Top Doctors who exhibit a long-standing commitment to their patients, Patients seeking the best care can find Castle Connolly's list of this year's Top Doctors on the website, http://www.castleconnolly.com, as well as in various partner publications, magazines and affiliate websites. This comprehensive resource ensures that patients can access the highest quality healthcare providers available.

Key Points: 
  • Castle Connolly, the trusted source for patients seeking top-tier healthcare providers, has recently recognized Dr. Maurice Khosh as one of the nation's leading doctors.
  • Dr. Khosh's nomination by his peers adds an extra layer of significance to this recognition.
  • As a double board-certified facial plastic surgeon , Dr. Khosh's extensive education and experience enable him to perform facial enhancements that are not only exceptional but also maintain a natural appearance.
  • He then pursued a fellowship in facial plastic surgery at the University of Washington in Seattle.

COULD WE LIVE TO 200? AN ERA OF SUPEROPTIMIZED HEALTHCARE IS ON ITS WAY, ACCORDING TO NEW HAVAS REPORT

Retrieved on: 
Monday, January 8, 2024

"The Superhuman era we're living in speaks to the paramount meaning of health in people's lives," said Eric Weisberg, Global Chief Creative Officer, Havas Health & You.

Key Points: 
  • "The Superhuman era we're living in speaks to the paramount meaning of health in people's lives," said Eric Weisberg, Global Chief Creative Officer, Havas Health & You.
  • Superoptimized Me: The rise of longevity science, medical gyms, and concierge medicine services offers a supercharged yet tailored and luxury approach to wellness.
  • In this Superhuman era of consumer-driven health, each one of us has the power to create our own health ecosystem."
  • Access the full report here and follow Havas on Instagram and LinkedIn for the latest research insights.

Weill Cornell Medicine to Open Medical Research Center at 1334 York Avenue

Retrieved on: 
Tuesday, November 28, 2023

Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.

Key Points: 
  • Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.
  • Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world.
  • The doctors and scientists of Weill Cornell Medicine—faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
  • Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital.

Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy

Retrieved on: 
Friday, November 10, 2023

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.
  • The first commercial procedures took place at NewYork-Presbyterian/Columbia University Irving Medical Center in New York City by Drs.
  • Paradise uRDN delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.
  • “This new renal denervation technology for a high-risk patient population – individuals with difficult to control hypertension – has been long awaited.

The Josh Bersin Company Introduces Systemic HR™, a Global Initiative to Redefine the Role of Human Resources in Business

Retrieved on: 
Tuesday, December 5, 2023

The Systemic HR Initiative, including a new study, The Definitive Guide to Human Resources: Systemic HR, from The Josh Bersin Company, is designed to help CHROs address these issues.

Key Points: 
  • The Systemic HR Initiative, including a new study, The Definitive Guide to Human Resources: Systemic HR, from The Josh Bersin Company, is designed to help CHROs address these issues.
  • "We believe adoption of the Systemic HR Initiative moves HR from a service delivery function to a proactive, solution-based consulting and advisory role."
  • Systemic HR research deliverables include a comprehensive research study, an organizational maturity model, Systemic HR Framework, specific action steps to move to Systemic HR, and a series of in-depth case studies describing the journey towards Systemic HR.
  • The Josh Bersin Company will also be launching a Systemic HR Awards program, starting at the company's annual executive conference, Irresistible 2024, to celebrate companies that embrace and implement the principles and practices of Systemic HR.